Home » Business, Health & Medicine, Hospitality » Fovista (Macular Edema and Macular Degeneration) Market Share, Size, Trends, Analysis and Forecasts To 2023 By Radiant Insights
“http://origin.grandviewresearc.netdna-cdn.com/img/logo.png”
Radiant Insights, Inc. included a detailed market survey and trends analysis on “Fovista (Macular Edema and Macular Degeneration) Market 2023”. This report also includes more info about basic overview of the industry including definitions, applications and industry china structure.

Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO).

Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector.

Browse full report on:
http://www.radiantinsights.com/research/fovista-macular-edema-and-macular-degeneration-forecast-and-market-analysis-to-2023

The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.

You can visit also linkedIn:
https://www.linkedin.com/pulse/fovista-macular-edema-degeneration-market-2023-dev-maskare?published=t

Fovista is a first-in-class anti-platelet-derived growth factor (anti-PDGF) agent being developed by Ophthotech for the treatment of wAMD as a combination therapy with an anti-VEGF drug, such as Lucentis, Avastin, or Eylea. The company is currently conducting a Phase III clinical program consisting of three large trials that are investigating the efficacy of Fovista combination therapy with anti-VEGF agents in comparison with anti-VEGF monotherapy, which is the current standard of care across the 7MM.

Scope

• Overview of Macular Edema and Macular Degeneration, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Fovista including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Fovista for the top country from 2013 to 2023.
• Sales information covered for the US, France, Germany, Italy, Spain, UK and Japan


About Us

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For More Information Visit: Radiant Insights


Visit Other Reports: 

OLED Material Market:
http://www.radiantinsights.com/research/global-and-chinese-oled-material-industry-2009-2019-market-research-report

Vinyl chloride-vinyl acetate copolymer paste resin Market:
http://www.radiantinsights.com/research/global-and-chinese-vinyl-chloride-vinyl-acetate-copolymer-paste-resin-industry-2009-2019-market-research-report

Media Contact
Company Name: Radiant Insights, Inc.
Contact Person: Michelle Thoras, Corporate Sales Specialist – USA
Email: sales@radiantinsights.com
Phone: (415) 349-0054, Toll Free: 1-888-202-9519
Address:28 2nd Street, Suite 3036
City: San Francisco
State: Califonia
Country: United States
Website: http://www.radiantinsights.com/research/fovista-macular-edema-and-macular-degeneration-forecast-and-market-analysis-to-2023

Comments are closed.